-
1
-
-
1242283946
-
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
-
Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 43:317-322.
-
(2004)
Lung Cancer
, vol.43
, pp. 317-322
-
-
Argiris, A.1
Mittal, N.2
-
2
-
-
4644294362
-
-
ESMO, Nice, France, October 18-22
-
Baselga J, Kris M, Yano S, et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 ('IRESSA') in locally advanced or metastatic non-small-cell lung cancer patients. ESMO, Nice, France, October 18-22, 2002.
-
(2002)
Phase II Trials (IDEAL 1 and IDEAL 2) of ZD1839 ('IRESSA') in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Patients
-
-
Baselga, J.1
Kris, M.2
Yano, S.3
-
3
-
-
0012381722
-
Multi-institutional randomized phase II traal of gefitinib for previously treated patients with advanced non-small-cell lung cancer
-
Fukuoka M, Yano S, Giaccone G, et al. Multi-Institutional Randomized Phase II Traal of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. Jour Clin Oncol 2003; 21:2237-46.
-
(2003)
Jour Clin Oncol
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
-
4
-
-
1542503756
-
Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
-
Giaccone G, Herbst RS, Manegold Ch, et al. Combining the Anti-EGFR Agent Gefitinib With Chemotherapy in Non-Small-Cell Lung Cancer: How Do We Go From INTACT to Impact? Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial - INTACT 1 Jour Clin Oncol 2004;22:759-761.
-
(2004)
Jour Clin Oncol
, vol.22
, pp. 759-761
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, Ch.3
-
5
-
-
1542503756
-
Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
-
Herbst RS, et al. Combining the Anti-EGFR Agent Gefitinib With Chemotherapy in Non-Small-Cell Lung Cancer: How Do We Go From INTACT to Impact? Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial - INTACT 2 Jour Clin Oncol 2004;22:759-761.
-
(2004)
Jour Clin Oncol
, vol.22
, pp. 759-761
-
-
Herbst, R.S.1
-
6
-
-
0142119289
-
Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis
-
Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. Jour Clin Oncol 2003;21:3798-3807.
-
(2003)
Jour Clin Oncol
, vol.21
, pp. 3798-3807
-
-
Hirsch, F.R.1
Varella-Garcia, M.2
Bunn Jr., P.A.3
-
7
-
-
0037811751
-
Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial?
-
Editorials
-
Johnson DH, Arteaga CL. Gefitinib in Recurrent Non-Small-Cell Lung Cancer: An IDEAL Trial? Jour Clin Oncol 2003;21Editorials:2227-29.
-
(2003)
Jour Clin Oncol
, vol.21
, pp. 2227-2229
-
-
Johnson, D.H.1
Arteaga, C.L.2
-
8
-
-
3242669300
-
The distribution of gefitinib ('Iressa', ZD1839) into mouse xenograft tumors
-
poster A-100
-
McKillop D, Stephens TC, Partridge EA, et al. The distribution of gefitinib ('Iressa', ZD1839) into mouse xenograft tumors. Clini Cancer Res A ACR-NCI-EORTC 2003;9(16 Pt 2 Suppl S):6093, poster A-100.
-
(2003)
Clini Cancer Res A ACR-NCI-EORTC
, vol.9
, Issue.16 PART 2 AND SUPPL. S
, pp. 6093
-
-
McKillop, D.1
Stephens, T.C.2
Partridge, E.A.3
-
9
-
-
1842509828
-
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
-
Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer. Jour Clin Oncol 2004; 22:1103-9.
-
(2004)
Jour Clin Oncol
, vol.22
, pp. 1103-1109
-
-
Miller, V.A.1
Kris, M.G.2
Shah, N.3
-
10
-
-
84862425464
-
Pre-operative induction gefitinib (Iressa, ZD 1839) treatment in a patient with relapsing bronchioloalveolar carcinoma
-
Madrid, Spain, 28. 6 - abstracts
-
Pešek M, Eliasová B. Pre-operative induction gefitinib (Iressa, ZD 1839) treatment in a patient with relapsing bronchioloalveolar carcinoma. Iressa Clinical Experience Meeting, Madrid, Spain, 28. 6. 2003 - abstracts.
-
(2003)
Iressa Clinical Experience Meeting
-
-
Pešek, M.1
Eliasová, B.2
-
11
-
-
1342268525
-
American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
-
Pfister DG, Jonhson DH, Azzoli ChG, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 Jour Clin Oncol 2004;22:330-353.
-
(2004)
Jour Clin Oncol
, vol.22
, pp. 330-353
-
-
Pfister, D.G.1
Jonhson, D.H.2
Azzoli, Ch.G.3
-
12
-
-
0033762484
-
The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents
-
Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000; 60:1-14.
-
(2000)
Drugs
, vol.60
, pp. 1-14
-
-
Rowinsky, E.K.1
-
13
-
-
85047691722
-
Gefitinib (Iressa): A novel treatment for non-small cell lung cancer
-
Vansteenkiste JF. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. Exp Rev Anti-cancer Ther 2004;4:5-17.
-
(2004)
Exp Rev Anti-cancer Ther
, vol.4
, pp. 5-17
-
-
Vansteenkiste, J.F.1
-
14
-
-
4644310711
-
Statistical analysis of survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib ('Iressa', ZD1839) in an expanded access program (EAP): Preliminary results
-
Wolf M, Farina Sisofo D, et al. Statistical analysis of survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib ('Iressa', ZD1839) in an expanded access program (EAP): Preliminary results. Eur J Cancer Supplements 2003;1:248.
-
(2003)
Eur J Cancer Supplements
, vol.1
, pp. 248
-
-
Wolf, M.1
Farina Sisofo, D.2
|